A PHASE 1, OPEN-LABEL, RANDOMIZED CROSSOVER STUDY TO COMPARE THE SINGLE-DOSE PHARMACOKINETICS OF TWO FORMULATIONS OF PF-07976016 ADMINISTERED ORALLY TO HEALTHY ADULT PARTICIPANTS
Latest Information Update: 10 Oct 2025
At a glance
- Drugs PF 07976016 (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 22 Sep 2025 Actual primary completion date changed from 14 Jan 2025 to 24 Dec 2024.
- 11 Mar 2025 Status changed from recruiting to completed.
- 11 Nov 2024 Status changed from not yet recruiting to recruiting.